A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

NCT07642024 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: BL-B01D1
DRUG: Osimertinib
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Cisplatin

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]